Atossa Therapeutics' Endoxifen Shows Promising Phase 2 Results, Secures Buy Rating
HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $6
Atossa Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)
Atossa Therapeutics Analyst Ratings
HC Wainwright & Co. Initiates Coverage On Atossa Therapeutics With Buy Rating, Announces Price Target of $4
Atossa Therapeutics Analyst Ratings
Atossa Therapeutics' Strong Financial Position and Promising Clinical Trials Drive Buy Rating: A Focus on Oral Endoxifen Breast Cancer Treatment
Atossa Stock Jumps 16% in Wake of Cantor Overweight Rating
Cantor Fitzgerald Initiates Coverage On Atossa Therapeutics With Overweight Rating, Announces Price Target of $5
Atossa Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Eiger Biopharmaceuticals (EIGR) and Atossa Therapeutics (ATOS)
Maxim Group Keeps Their Buy Rating on Atossa Therapeutics (ATOS)
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS) and Karuna Therapeutics (KRTX)
Maxim Group Sticks to Its Buy Rating for Atossa Therapeutics (ATOS)
No Data